Brand-name cardio drugs no more effective than generics, researchers say

January 2009
Pharmacy Today;Jan2009, Vol. 15 Issue 1, p2
The article reports on the statement by researchers that evidence does not support the notion that brand-name drugs used in cardiovascular disease are superior to generic drugs. Trials identify generic and brand-name drugs clinical equivalence in all research on beta-blockers, antiplatelet agents, statins, angiotensin converting enzyme (ACE) inhibitors, and alpha-blockers. Researchers concluded that brand-name drugs had no statistically important superiority to generic drugs.


Related Articles

  • LIPITOR VS. SIMVASTATIN FOR EFFICACY OF CARDIOVASCULAR EVENT AND MORTALITY REDUCTION.  // Ethnicity & Disease;Summer2009 Supplement 3, Vol. 19 Issue 3, p35 

    Millions of Americans have hypercholesterolemia, placing them at excess risk for cardiovascular disease. As a result, patients desire affordable, effective methods to help combat high cholesterol with HMG-CoA reductase inhibitors (statins). Both Lipitor (branded medication) and simvastatin...

  • Researchers recommend statin therapy for diabetes.  // Practice Nurse;1/25/2008, Vol. 35 Issue 2, p8 

    The article reports on a study which showed that most people with diabetes should be considered for statin therapy regardless of whether or not they already have cardiovascular disease. An analysis of 14 randomised trials has shown that statins cut the risk of heart attack, stroke and death in...

  • Independent Nurse: Call to boost statin therapy adherence.  // GP: General Practitioner;1/29/2010, p10 

    The article reports on a study in Great Britain, which suggests that improving adherence to statin therapy would have more impact than increasing its use. Researchers compared the effect of increasing adherence by 50 per cent with the effect of reducing the risk threshold for prescribing statins...

  • C-Reactive Protein, LDL and Statin Therapy.  // Diabetes Health;May2005, Vol. 14 Issue 5, p64 

    Provides information on the results of the multicenter PROVE IT-TIMI 22 clinical trials regarding the relationships between C-reactive protein (CRP) levels with low-density lipoprotein (LDL) cholesterol after statin treatments as of May 2005. Number of patients who were involved in the study;...

  • Statin Discontinuation in High-Risk Patients: A Systematic Review of the Evidence. Sandoval, Yessica-Haydee Gomez; Braganza, Michael V.; Daskalopoulou, Stella S. // Current Pharmaceutical Design;11/11/2011, Vol. 17 Issue 33, p3669 

    Hypercholesterolemia is a major risk factor for cardiovascular disease (CVD), the leading cause of death worldwide. Since the late 1980s, statins have emerged as effective lipid-lowering therapies and are now widely used to protect against and slow the progression of CVD and cerebrovascular...

  • THIS WEEK IN JAMA. Meyer, Catherine // JAMA: Journal of the American Medical Association;7/23/2003, Vol. 290 Issue 4, p435 

    The topics of medical research appearing in this issue of "JAMA" include long-term risk of breast cancer in Hodgkin disease, cancer and mortality risk with antioxidant supplements, acarbose therapy and risk for cardiovascular disease in patients with impaired glucose tolerance, failure to...

  • Evidence for Pleiotropic Effects of Statins in Clinical Trials. Ping-Yen Liu; Chao-Yung Wang; Liao, James K. // Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry;Jun2008, Vol. 8 Issue 2, p116 

    Lipid-lowering agents, such as 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, also known as statins, have been shown to reduce cardiovascular events. However, evidence from recent clinical trials suggests that the beneficial effects of statins may be derived from both...

  • Predicting the potential effect of JUPITER. Weintraub, Howard; Gagarin, Dimitri // Endocrine Today;11/10/2008, Vol. 6 Issue 20, p22 

    The author reflects on the potential effect of the JUPITER study, which is intended to determine whether long-term treatment with rosuvastatin would reduce the rate of cardiovascular events in healthy men and women. The exclusion criteria was extensive as all chronic inflammatory conditions...

  • FIBRATY W TERAPII SKOJARZONEJ -- SKUTECZNOŚၪ I BEZPIECZEŃSTWO. Broncel, Marlena; Koziróg-Kołacińska, Marzena // Problemy Terapii Monitorowanej;jun2007, Vol. 18 Issue 2, p111 

    It has been proved by great clinical trials that LDL-cholesterol (LDL-C) level reduction reduces not only acute coronary syndromes frequency but also cardiovascular morbidity and mortality. It seems that modification of triglycerides (TG) and HDL-cholesterol (HDL-C) levels can result in further...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics